2014-04-17 04:43:01 - RANBAXY - Stretched Balance Sheet, a Weak Product Pipeline, and Uncertainty around Monetizing Exclusivities - a new market research report on companiesandmarkets.com
Q2 CY-13 Result in Line: Sales grew by 8% QoQ primarily on account of higher Absorica (Isotretinoin) sales in US. US sales grew by 29% sequentially as company now has 14% share in Isotretinion (~$400m market). Excluding US, revenue across the geographies remained muted and grew by 1% sequentially and 2% yoy.
EBITDA margin at 9.8%, has improved by 220 bps on sequential basis mainly due to high margin sales of Isotretinoin and INR depreciation. Forex loss of Rs.5403m and impairment of goodwill of Rs.1192m in France resulted in loss of Rs5242m at net level.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.